Dipeptidyl peptidase 4 inhibitors - Pipeline Insight, 2024

This “Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dipeptidyl Peptidase 4 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dipeptidyl Peptidase 4 Inhibitors Understanding

Dipeptidyl Peptidase 4 Inhibitors: Overview

Dipeptidyl-peptidase-4 (DPP4, also known as CD26) is a membrane glycoprotein that is well known for its role in the catalytic degradation of incretins. DPP4 inhibitors (DPP4i), as a class of antidiabetic medications, have been accepted worldwide, owing to their ease of administration, modest effects on HbA1c, and lack of serious side effects. DPP4 inhibition in experimental models has uniformly demonstrated cardioprotective effects.

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and may be used in the treatment of type 2 diabetes. DPP-4 inhibitors slow the inactivation and degradation of GLP-1, a hormone involved in glucose removal from the gut. DPP-4 inhibitors improve blood glucose control and reduce both fasting and postprandial (after food) blood glucose levels, without causing weight gain. They do not usually cause hypoglycemia (low blood sugar levels) unless they are combined with other therapies that cause hypoglycemia.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dipeptidyl Peptidase 4 Inhibitors R&D. The therapies under development are focused on novel approaches for Dipeptidyl Peptidase 4 Inhibitors.

Dipeptidyl Peptidase 4 Inhibitors Emerging Drugs Chapters

This segment of the Dipeptidyl Peptidase 4 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dipeptidyl Peptidase 4 Inhibitors Emerging Drugs

HSK7653: Haisco Pharmaceutical Group HSK7653 is a new oral drug for the treatment of type 2 diabetes with independent intellectual property rights developed by Haisco. It is intended to be used for the treatment of type 2 diabetes. HSK7653, as a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), can increase the plasma levels of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) Concentration, promotes insulin secretion in a glucose concentration-dependent manner, and ultimately improves blood sugarcontrol.

It is currently in Phase III stage of development and is being developed by Haisco Pharmaceutical Group.

DA-1229: Dong-A STDA-1229 is an orally available small molecule agonist of the thyroid hormone receptor that is being approved for Type 2 diabetes mellitus but it is currently in Phase II stage of development for the treatment of Calcific Aortic Valve Disease and is being developed by Dong-A ST.

Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Dipeptidyl Peptidase 4 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Dipeptidyl Peptidase 4 Inhibitors

There are approx. 8+ key companies which are developing the Dipeptidyl Peptidase 4 Inhibitors. The companies which have their Dipeptidyl Peptidase 4 Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Haisco Pharmaceutical Group.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dipeptidyl Peptidase 4 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dipeptidyl Peptidase 4 Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dipeptidyl Peptidase 4 Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dipeptidyl Peptidase 4 Inhibitors drugs.

Dipeptidyl Peptidase 4 Inhibitors Report Insights

• Dipeptidyl Peptidase 4 Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dipeptidyl Peptidase 4 Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Dipeptidyl Peptidase 4 Inhibitors drugs?
• How many Dipeptidyl Peptidase 4 Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Dipeptidyl Peptidase 4 Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dipeptidyl Peptidase 4 Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dipeptidyl Peptidase 4 Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boehringer Ingelheim
• Haisco Pharmaceutical Group
• Bio XcelTherapeutics
• Recardio
• Dong-A ST
• CSPC ZhongQi Pharmaceutical Technology
• Chia Tai Tianqing Pharmaceutical Group

Key Products

• Linagliptin
• HSK7653
• BXCL 701
• Dutogliptin
• DA-1229
• DBPR108
• TQ-F3083

This product will be delivered within 2 business days.